602 related articles for article (PubMed ID: 17493020)
1. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
Clausen J; Wolf D; Petzer AL; Gunsilius E; Schumacher P; Kircher B; Gastl G; Nachbaur D
Clin Exp Immunol; 2007 Jun; 148(3):520-8. PubMed ID: 17493020
[TBL] [Abstract][Full Text] [Related]
2. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
[TBL] [Abstract][Full Text] [Related]
3. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation.
Verheyden S; Schots R; Duquet W; Demanet C
Leukemia; 2005 Aug; 19(8):1446-51. PubMed ID: 15973456
[TBL] [Abstract][Full Text] [Related]
4. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
[TBL] [Abstract][Full Text] [Related]
5. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients.
Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
Eur J Haematol; 2007 Apr; 78(4):338-46. PubMed ID: 17378893
[TBL] [Abstract][Full Text] [Related]
6. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
[TBL] [Abstract][Full Text] [Related]
7. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
[TBL] [Abstract][Full Text] [Related]
8. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
9. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
[TBL] [Abstract][Full Text] [Related]
10. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component.
Hsu KC; Pinto-Agnello C; Gooley T; Malkki M; Dupont B; Petersdorf EW
Tissue Antigens; 2007 Apr; 69 Suppl 1():42-5. PubMed ID: 17445161
[TBL] [Abstract][Full Text] [Related]
13. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
14. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders.
Chen C; Busson M; Rocha V; Appert ML; Lepage V; Dulphy N; Haas P; Socié G; Toubert A; Charron D; Loiseau P
Bone Marrow Transplant; 2006 Sep; 38(6):437-44. PubMed ID: 16892071
[TBL] [Abstract][Full Text] [Related]
15. Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients.
Linn YC; Phang CY; Lim TJ; Chong SF; Heng KK; Lee JJ; Loh Y; Hwang W; Goh YT; Koh M
Bone Marrow Transplant; 2010 Jun; 45(6):1031-7. PubMed ID: 19898503
[TBL] [Abstract][Full Text] [Related]
16. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts.
Michaelis SU; Mezger M; Bornhäuser M; Trenschel R; Stuhler G; Federmann B; Oevermann L; Kanz L; Handgretinger R; Bethge WA
Ann Hematol; 2014 Sep; 93(9):1579-86. PubMed ID: 24771045
[TBL] [Abstract][Full Text] [Related]
17. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus reactivation after matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant correlates with donor killer immunoglobulin-like receptor genotype.
Sobecks RM; Askar M; Thomas D; Rybicki L; Kalaycio M; Dean R; Avery R; Mossad S; Copelan E; Bolwell BJ
Exp Clin Transplant; 2011 Feb; 9(1):7-13. PubMed ID: 21605017
[TBL] [Abstract][Full Text] [Related]
19. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
[TBL] [Abstract][Full Text] [Related]
20. Role of killer immunoglobulin-like receptor-ligand interactions in human leukocyte antigen-matched sibling hematopoietic stem cell transplantation.
Kanga U; Mourya M; Seth T; George J; Sood P; Sharma R; Saxena A; Mehra NK
Transplant Proc; 2012 May; 44(4):919-21. PubMed ID: 22564585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
